Harbour BioMed, Moderna partner on immunotherapies development
The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces